Ärztliches Berufsrecht Patientenkartei und Praxisübernahme

  • Published 2001 in Der Internist

Abstract

768 46. Kolb HJ, Mittermuller J, Clemm C et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462–2465 47. Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041–2050 48. Bertz H, Burger JA, Kunzmann R et al. (1997) Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graftversus-myeloma effect. Leukemia 11: 281–283 49. Dazzi F, Szydlo RM, Goldman JM (1999) Donor lymphocyte infusions for relapse of chronic myeloid leukemia after stem cell transplant: Where we now stand. Exp Hematol 27: 1477–1486 50. Bertz H, Kunzmann R, Bunjes D, Finke J (1998) Successful adoptive immunotherapy for relaps of AML 9 years after T-cell depleted BMT. Br J Haematol 103: 563–564 51. Drobyski WR, Hessner MJ, Klein JP et al. (1999) T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94: 434–441 52. Mackinnon S, Papadopoulos EB, Carabasi MH et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graftversus-leukemia responses from graft-versushost disease. Blood 86: 1261–1268 53. Alyea EP, Soiffer RJ, Canning C et al. (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 15: 3671–3680 54. Bonini C, Ferrari G,Verzeletti S et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 13: 1719–1724 55. Mutis T,Verdijk R, Schrama E et al. (1999) Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted histocompatibility antigens. Blood 93: 2336–2341 56. Miller JS, Klingsporn S, Lund J et al. (1994) Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 14: 555–562 57. Koerner K, Cardoso M, Dengler T, Kerowgan M, Kubanek B (1998) Estimated risk of transmission of Hepatitis C Virus by blood transfusion.Vox Sang 74: 213–216 58. Seifried E, Roth WK (2000) Optimal blood donation screening. Annot Br J Haematol 109: 694–698 Patientenkartei und Praxisübernahme

DOI: 10.1007/s001080170144

Cite this paper

@article{2001rztlichesBP, title={{\"Arztliches Berufsrecht Patientenkartei und Praxis{\"{u}bernahme}, author={}, journal={Der Internist}, year={2001}, volume={42}, pages={A768-A768} }